Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor, covering 2019-05-07 to 2019-05-07. Get the full timeline:
Most recent: Clinical Trial Update: Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection [Phase 2]